Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland
Background: Following the spread of the coronavirus disease 2019 (COVID-19) pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C). In the absence of trials,...
Saved in:
Similar Items
-
Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY Trial
by: Tatjana Welzel, et al.
Published: (2022) -
Case Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Switzerland
by: Athina Fouriki, et al.
Published: (2021) -
Editorial: Sepsis in Neonates and Children
by: Eric Giannoni, et al.
Published: (2020) -
The Role of Parental Concerns in the Recognition of Sepsis in Children: A Literature Review
by: Amanda Harley, et al.
Published: (2019) -
Sepsis: Changing Definitions, Unchanging Treatment
by: Nchafatso Gikenyi Obonyo, et al.
Published: (2019)